Study Week News Today

Takeda Announces China NMPA Approval of LIVTENCITY maribavir for the Treatment of Adults With Posttransplant Cytomegalovirus CMV Refractory to Prior Therapies

In the December 1960 / January 1961 issue of the NICAP UFO Investigator journal, a small article was published under the

In the December 1960 / January 1961 issue of the NICAP UFO Investigator journal , a small article was published under the

If Approved, Maribavir Would be the First and Only Inhibitor of CMV-specific UL97 Protein Kinase in the EU for Treatment of Adults with Post-transplant CMV Refractory (With or Without Resistance) to

Data Include Exploratory Analysis Showing LIVTENCITY Treated Patients With Post-Transplant Cytomegalovirus (CMV) Infections/Disease Had Reductions in Hospitalizations (34.8%; p=0.021) and Length

Georgian College students can expect to learn remotely until early March.

TOKYO (dpa-AFX) - Takeda Pharmaceutical Company Limited (TAK) said that a subgroup analysis from phase 3 clinical trial supported efficacy of the investigational drug TAK-620 or maribavir over